M1069

M1069 is a selective and orall active, dual A2A/A2B adenosine receptor antagonist with a selectivity of >100 fold against the A1 and A3 receptors. M1069 counteracts immune-suppressive mechanisms of adenosine, and exhibits anti-tumor activity[1][2][3].

Product Specifications

CAS Number

[3027658-65-4]

UNSPSC

12352005

Target

Adenosine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/m1069.html

Purity

98.04

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

COC1=C2C(SC(NC(N3C[C@]4(CCCOC4)CC3)=O)=N2)=C(C5=CCOCC5)C=N1.O=C(O)/C=C/C(O)=O

Molecular Formula

C25H30N4O8S

Molecular Weight

546.59

References & Citations

[1]Rinat Zaynagetdinov, et al. Abstract 3499: M1069 as dual A2A/A2B adenosine receptor antagonist counteracts immune-suppressive mechanisms of adenosine and reduces tumor growth in vivo. Cancer Res (2022) 82 (12_Supplement) :3499. |[2]Lillian L Siu, et al. Abstract CT240: A first-in-human study of the dual A2A/A2B adenosine receptor antagonist M1069 in patients with advanced solid tumors. Cancer Res (2022) 82 (12_Supplement) :CT240. |[3]Tanzer Eva-Maria, et al. Preparation of thiazolopyridine derivatives as adenosine receptor antagonists: World Intellectual Property Organization, WO2020152132[P]. 2020-07-30.